Salute e Benessere

Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to…

Management Comments Management Comments Iris Bincovich, the CEO of Innocan commented:"We are very pleased with our performance in 2023, closing the year with a strong fourth quarter. This was due to the strong execution by our team in the quarter as well as throughout the year. We delivered impactful, customer-centric innovation and thoughtfully managed all aspects of our operation. Our accomplishments during the year as well as our progress on executing on our strategy has enabled us...
PR Newswire
01/04/2024

Oncoclínicas&Co has revenues of R$6 billion and profit of R$313 million in 2023

In 2023, gross cash profit totaled R$1.9 billion, corresponding to a margin of 35.4%, which represents an increase of 33.7% over that reported in 2022. EBITDA totaled R$1.0 billion for the entire year (R$1.1 billion excluding the non-cash effect of the long-term incentive plan accounting calculation, or on an ex-PILP basis), 58.9% above 2022, reflecting not only the Company's revenue growth, but also efficiency gains captured in the operation. In 2023, gross cash profit totaledR$1.9 billion,...
PR Newswire
01/04/2024

Endo, Inc. Announces Proposed New Senior Secured Credit Facilities

Endo currently expects the Plan to be effective on or around April 23, 2024. Endo currently expects the Plan to be effective on or aroundApril 23, 2024. The New Credit Facilities are subject to market and other conditions and are anticipated to close substantially concurrently with the effectiveness of the Plan. However, there can be no assurance that the New Credit Facilities will be consummated on the terms described herein or at all. About Endo, Inc.Endo, Inc. was recently formed...
PR Newswire
01/04/2024

Rapid Microbiology Testing Market Worth $8.3 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=31548521 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=31548521 Browse in-depth TOC on "Rapid Microbiology Testing Market" 318 - Tables 45 - Figures 331 - Pages Rapid Microbiology Testing Market Scope: In 2023, the instruments segment held the largest share of the rapid microbiology testing market by product segment. Based...
PR Newswire
01/04/2024

Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute Center…

The Request for Proposals (RFP) is open to academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada, and the United Kingdom. Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer's field are strongly encouraged to apply. The Request for Proposals (RFP) is open to academic investigators at accredited medical centers, research institutions, and universities inthe United...
PR Newswire
01/04/2024

Surface Disinfection Market to Reach $5.6 billion, Globally, by 2032 at 7.4%…

Prime determinants of growth Prime determinants of growth The surface disinfectant market is fueled by factors such as surge in hospital-acquired infections, higher healthcare spending, and broad applications of surface disinfectant in non-healthcare sectors. Stringent regulations regarding surface disinfectant use and hazardous chemical handling restrain market growth. Nevertheless, advancements in production processes and the emergence of eco-friendly disinfectant alternatives offer...
PR Newswire
01/04/2024

ThinkCyte advances biopharma phenotypic drug discovery programs with publication…

The publication comes on the heels of an invited talk at the Society for Laboratory for Automation and Screening (SLAS) meeting in February where ThinkCyte presented how VisionSort was used to perform flow-based high content intracellular phenotypic screening using DNA barcoding technology. In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening. The publication comes on the heels of an invitedtalkat the...
PR Newswire
01/04/2024

IMC applauds the April 1st implementation of the new Israeli cannabis…

The reform, announced by the Israeli ministry of health onAugust 7, 2023, underwent a three-month delay due to the Israel-Hamas war following its initial announcement (the " Reform "). The Reform will be implemented in phases, as approved, and announced by the Israeli Ministry of Health. The key aspects of the initial phase, commencing today,April 1st, are as follows: "We believe that by facilitating the access to medical cannabis, for many new patients, the new regulations...
PR Newswire
01/04/2024

Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic…

The tools, each of which play a critically important role in the assessment process, include: EpiMatrix for T cell epitope mapping, ClustiMer for the identification of epitope-dense regions that could be key to further testing/deimmunization, JanusMatrix for characterizing epitopes (the identification of potentially tolerated or actively tolerogenic epitopes, like Tregitopes), and OptiMatrix for sequence modifications to mitigate immunogenic risks. The tools, each of which play a critically...
PR Newswire
01/04/2024

Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe…

Mr. Arkin added, "I look forward to working more closely with Lutris Pharma's management team and Board as we work to fulfill our mission to improve anti-cancer therapy effectiveness, as well as the quality of life for patients who develop EGFR inhibitor-induced acneiform lesions or radiation-induced dermatitis." Mr. Arkin added, "I look forward to working more closely with Lutris Pharma's management team and Board as we work to fulfill our mission to improve anti-cancer therapy…
PR Newswire
01/04/2024

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent…

BOSTON and LONDON, April01, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. “Amidst challenging economic conditions during 2023 in the biotech sector and beyond, the Akari team advanced our Phase 3 and pre-clinical development programs and paved the way for a merger that, upon...
Nasdaq GlobeNewswire
01/04/2024

Hairbrush Market to Reach $6.4 Billion, Globally, by 2033 at 4.8% CAGR: Allied…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/3122 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/3122 The growing salon and beauty parlors industry in emerging nations likeIndiaandChinais expected to fuel the market growth in the foreseeable future. The global hairbrush market has witnessed significant growth due to factors such as surge in disposable income, change in fashion...
PR Newswire
01/04/2024

Sixth Appearance at Boao Forum for Asia: Yili Demonstrates Innovative Vigor to…

Yili is focusing on innovating its industrial chain to address technological bottlenecks across the entire chain, providing consumers with higher-quality products and services. By establishing a globally influential hub for technological innovation, Yili is enhancing its core competitiveness. Moreover, it is upgrading digitization throughout every link in the industrial chain to improve operational efficiency and facilitate business development. Yili is focusing on innovating its industrial...
PR Newswire
01/04/2024

Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the…

Eisai had aimed to submit a Biologics License Application (BLA) for weekly maintenance therapy using subcutaneous (SC) administration in March 2024. To respond to the FDA's recent requirement of additional three-month immunogenicity data at the proposed maintenance dose of 360 mg weekly, Eisai planned to initiate a rolling BLA for lecanemab SC maintenance in the first quarter 2024, under lecanemab's existing Fast Track and Breakthrough Therapy designations.[2] However, Eisai was recently…
PR Newswire
01/04/2024

Total number of shares and voting rights in Zealand Pharma at March 31, 2024

Company announcement – No. 21 / 2024 Total number of shares and voting rights in Zealand Pharma at March 31, 2024 Copenhagen, Denmark, March 31, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end...
Nasdaq GlobeNewswire
31/03/2024

Winner of Best Box Award, VOOPOO Shines at VAPEXPO 2024

In addition to their award-winning DRAG S2, VOOPOO made a significant impact at VAPEXPO 2024 with their star product taking center stage. The VOOPOO's first vape with powerbank, DORIC Galaxy, arrived at the expo and attracted many enthusiasts to try it. Besides, ARGUS Pod Family, ARGUS PRO, and other star products captured the attention of attendees and industry professionals alike. In addition to their award-winning DRAG S2, VOOPOO made a significant impact at VAPEXPO 2024 with their star...
PR Newswire
30/03/2024

Information on the total number of voting rights and shares

REGULATED INFORMATIONInformation on the total number of voting rights and sharesMont-Saint-Guibert(Belgium), March 29, 2024 , 9:30 pm CET / 4:30 pm ET –In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 4,927,355.12 Total number of securities carrying voting rights: 28,682,635 (all ordinary...
Nasdaq GlobeNewswire
29/03/2024

Closed System Transfer Devices Market Worth $2.5 billion | MarketsandMarkets™

Browse in-depth TOC on "Closed System Transfer Devices Market" Browse in-depth TOC on "Closed System Transfer Devices Market" 150 - Tables 70 - Figures 250 - Pages Closed System Transfer Devices Market Scope: Closing mechanism system is expected to grow at the highest CAGR during the forecast period. Based on the closing mechanism, the market is segmented into Luer lock systems, push-to-turn systems, click-to-lock systems, and color-to-color alignment systems...
PR Newswire
29/03/2024

Aohua Endoscopy's AQ-300 is Recognized as "Endoscopy Product Innovation Award"…

The AQ-300 is equipped with a newly developed image processing system with 4K images to provide more details with a wider color gamut to present colour more realistically and reduce visual error. The AQ-300 is equipped with a newly developed image processing system with4Kimages to provide more details with a wider color gamut to present colour more realistically and reduce visual error. When used in conjunction with Aohua's magnification endoscope, AQ-300 can guarantee that the image is...
PR Newswire
29/03/2024

BioSenic S.A. : Information on the total number of voting rights and shares

PRESS RELEASE – REGULATED INFORMATIONMont-Saint-Guibert, Belgium, March 29, 2024, 7.00 am CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication...
Nasdaq GlobeNewswire
29/03/2024

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides…

FINANCIAL HIGHLIGHTSTotal revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022...
Nasdaq GlobeNewswire
29/03/2024

UV Nail Gel Market Projected to Reach $147.98 million by 2030 - Exclusive Report…

UV nail gels have emerged as a coveted nail enhancement choice in an era where personal grooming and aesthetic appeal are more important. These gels, known for their durability, luxurious glossy finish, and resistance to everyday wear and tear, require a curing process under UV light, transforming them into a robust protective layer. This market growth is fueled by advancements in UV technology, making these products safer and more accessible, and a global surge in disposable income, empowering…
PR Newswire
29/03/2024

Central Lab Market Projected to Reach $5.78 billion by 2030 - Exclusive Report…

Central laboratories are becoming increasingly vital in clinical research, offering top-notch and uniform testing services to clinical trial sites worldwide. These labs are crucial for ensuring data accuracy, consistency, and reliability. These are essential for successful clinical research. The growing need for specialized testing, a rise in global clinical trials, and the pharmaceutical industry's trend toward outsourcing to boost efficiency are propelling the need for central labs forward…
PR Newswire
29/03/2024

Personalized Nutrition Market Projected to Reach $38.22 billion by 2030 -…

Personalized nutrition marks a transformative approach to diet management and nutritional care, catering to individual health requirements through genetic insights, lifestyle patterns, dietary habits, and specific health objectives. This innovative strategy facilitates weight control and metabolic health improvement and ensures tailored dietary interventions for enhanced well-being. The global market for personalized nutrition is witnessing substantial growth, driven by a heightened focus on…
PR Newswire
29/03/2024
Altri  Comunicati